Hit discovery or hit identification in drug development is driven by the need to identify small molecules with desirable activity in a compound screen against a target. Our state-of-the-art fully automated robotic platform is set-up to accelerate your drug discovery process starting with robust, targeted hit identification services. Our system can efficiently run biochemical, phenotypic and cellular HTS assays in 384- or 1536-well formats.

Bring your own library or use one of our compound libraries in a small molecule hit identification and validation platform that combines a comprehensive range of HTS screening technologies including fluorescence intensity, FRET, luminescence, BRET, absorbance, fluorescence polarization, TR-FRET, time-resolved fluorescence, Alpha screen, AlphaLISA, qPCR, mass spectrometry assays and more.